CN113896771A - Polypeptide for promoting swine organisms to generate African swine fever virus antigen specific immune response and application thereof - Google Patents
Polypeptide for promoting swine organisms to generate African swine fever virus antigen specific immune response and application thereof Download PDFInfo
- Publication number
- CN113896771A CN113896771A CN202111307559.5A CN202111307559A CN113896771A CN 113896771 A CN113896771 A CN 113896771A CN 202111307559 A CN202111307559 A CN 202111307559A CN 113896771 A CN113896771 A CN 113896771A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- immune response
- promoting
- swine fever
- fever virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 133
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 133
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 131
- 241000701386 African swine fever virus Species 0.000 title claims abstract description 58
- 241000282898 Sus scrofa Species 0.000 title claims abstract description 37
- 239000000427 antigen Substances 0.000 title claims abstract description 36
- 102000036639 antigens Human genes 0.000 title claims abstract description 36
- 108091007433 antigens Proteins 0.000 title claims abstract description 36
- 230000028993 immune response Effects 0.000 title claims abstract description 31
- 230000001737 promoting effect Effects 0.000 title claims abstract description 27
- 229940031626 subunit vaccine Drugs 0.000 claims abstract description 23
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 22
- 210000002540 macrophage Anatomy 0.000 claims abstract description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 14
- 102100037850 Interferon gamma Human genes 0.000 claims abstract description 6
- 108010074328 Interferon-gamma Proteins 0.000 claims abstract description 6
- 230000028327 secretion Effects 0.000 claims description 16
- 230000035755 proliferation Effects 0.000 claims description 15
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000007972 injectable composition Substances 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 abstract description 18
- 229920000642 polymer Polymers 0.000 abstract description 17
- 241001465754 Metazoa Species 0.000 abstract description 3
- 230000000379 polymerizing effect Effects 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract 1
- 241000282887 Suidae Species 0.000 description 14
- 210000004698 lymphocyte Anatomy 0.000 description 10
- 238000001819 mass spectrum Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 6
- 208000007407 African swine fever Diseases 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 235000013882 gravy Nutrition 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000003393 splenic effect Effects 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- DECCMEWNXSNSDO-ZLUOBGJFSA-N Ala-Cys-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O DECCMEWNXSNSDO-ZLUOBGJFSA-N 0.000 description 1
- AOAKQKVICDWCLB-UWJYBYFXSA-N Ala-Tyr-Asn Chemical compound C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N AOAKQKVICDWCLB-UWJYBYFXSA-N 0.000 description 1
- PRLPSDIHSRITSF-UNQGMJICSA-N Arg-Phe-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PRLPSDIHSRITSF-UNQGMJICSA-N 0.000 description 1
- HNXWVVHIGTZTBO-LKXGYXEUSA-N Asn-Ser-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O HNXWVVHIGTZTBO-LKXGYXEUSA-N 0.000 description 1
- PQKSVQSMTHPRIB-ZKWXMUAHSA-N Asn-Val-Ser Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O PQKSVQSMTHPRIB-ZKWXMUAHSA-N 0.000 description 1
- LTCKTLYKRMCFOC-KKUMJFAQSA-N Asp-Phe-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(O)=O LTCKTLYKRMCFOC-KKUMJFAQSA-N 0.000 description 1
- KPSHWSWFPUDEGF-FXQIFTODSA-N Asp-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC(O)=O KPSHWSWFPUDEGF-FXQIFTODSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LJEPDHWNQXPXMM-NHCYSSNCSA-N Gln-Arg-Val Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(O)=O LJEPDHWNQXPXMM-NHCYSSNCSA-N 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- WUGMRIBZSVSJNP-UHFFFAOYSA-N N-L-alanyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)C)C(O)=O)=CNC2=C1 WUGMRIBZSVSJNP-UHFFFAOYSA-N 0.000 description 1
- YEEFZOKPYOUXMX-KKUMJFAQSA-N Phe-Gln-Met Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCSC)C(O)=O YEEFZOKPYOUXMX-KKUMJFAQSA-N 0.000 description 1
- RCYUBVHMVUHEBM-RCWTZXSCSA-N Pro-Pro-Thr Chemical compound [H]N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O RCYUBVHMVUHEBM-RCWTZXSCSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- SZRNDHWMVSFPSP-XKBZYTNZSA-N Ser-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CO)N)O SZRNDHWMVSFPSP-XKBZYTNZSA-N 0.000 description 1
- LGNBRHZANHMZHK-NUMRIWBASA-N Thr-Glu-Asp Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N)O LGNBRHZANHMZHK-NUMRIWBASA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000012224 gene deletion Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 230000007124 immune defense Effects 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000006759 inflammatory activation Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940126583 recombinant protein vaccine Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940124856 vaccine component Drugs 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides a polypeptide for promoting a pig organism to generate African swine fever virus antigen specific immune response and application thereof, belonging to the technical field of biological medicine; the polypeptide comprises one or more of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide and a fifth polypeptide; the amino acid sequences of the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide are respectively shown as SEQ ID NO. 1-SEQ ID NO. 5. The polypeptide can obviously promote ASFV sensitized immune cells to proliferate, and can promote a pig organism to generate ASFV antigen specific immune response by promoting pig mononuclear macrophages and B, T lymphocytes to secrete IFN-gamma. After animals are immunized, the immune response of the pig organism can be remarkably promoted. The polypeptide or the polypeptide polymer obtained by polymerizing the polypeptide can be used for preparing subunit vaccines of African swine fever viruses.
Description
The application is a divisional application with the application date of 26/08/2020, the application number of CN202010873520.9, and the name of the invention is polypeptide for promoting a pig organism to generate African swine fever virus antigen specific immune response and application thereof.
Technical Field
The invention relates to the technical field of biomedicine, in particular to a polypeptide for promoting a pig organism to generate African swine fever virus antigen specific immune response and application thereof.
Background
African Swine Fever (ASF) is an acute, hemorrhagic, virulent infectious disease caused by African Swine Fever Virus (ASFV) infecting domestic pigs and various wild pigs (such as African wild pigs, European wild pigs, etc.). African swine fever virus mainly infects immune cells such as macrophages and monocytes, and after infection, ASFV escapes the innate and inherent immune defense systems of a host through different mechanisms, such as type I Interferon (IFN) response, apoptosis, inflammatory response and activation of specific target genes.
Vaccines are among the most effective methods for preventing african swine fever. Traditional attenuated live and inactivated vaccines are currently the most commonly used vaccines. However, the natural attenuated strain of ASFV or the attenuated strain caused by gene deletion has many defects such as biological potential safety hazard, immune side reaction, toxin dispersing danger, genetic background unclear and the like, so the application of the ASFV in vaccine production is limited. ASFV encodes up to 167 proteins, which makes it extremely difficult to screen candidate antigens that induce immune protection in the body. However, several proteins have been reported as targets for virus neutralization and recombinant protein vaccine studies have been performed on them. The two proteins, P30 and P54, are located outside the virus and are involved in viral adsorption and internalization, respectively. The p30 and p54 proteins are used for immunizing domestic pigs to induce the generation of neutralizing antibodies, but cannot resist lethal challenge, and the disease course is not changed, while the p30 and p54 combined vaccine is used for immunizing domestic pigs to generate the neutralizing antibodies and improve the disease course. Inova et al evaluated 46 peptides that mimic viral proteins to determine their ability to mount protective immune responses. Vaccination with certain combination peptides delayed the death of the pigs. However, to date, no fully effective ASFV subunit vaccine has been reported.
Disclosure of Invention
The polypeptide can be used for preparing ASFV subunit vaccine, and the prepared subunit vaccine can effectively enhance the ASFV specific immune response of the organism and prevent African swine fever virus infection.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides a polypeptide for promoting a pig body to generate African swine fever virus antigen specific immune response; the polypeptide comprises one or more of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide and a fifth polypeptide;
the amino acid sequence of the first polypeptide is shown as SEQ ID NO. 1;
the amino acid sequence of the second polypeptide is shown as SEQ ID NO. 2;
the amino acid sequence of the third polypeptide is shown as SEQ ID NO. 3;
the amino acid sequence of the fourth polypeptide is shown as SEQ ID NO. 4;
the amino acid sequence of the fifth polypeptide is shown as SEQ ID NO. 5;
the polypeptide promotes a pig body to generate an African swine fever virus antigen specific immune response by promoting the secretion of IFN-gamma by pig mononuclear macrophage and B, T lymphocyte; and/or the presence of a gas in the gas,
the polypeptide promotes a pig body to generate African swine fever virus antigen specific immune response by promoting ASFV antigen specific mononuclear macrophage proliferation.
Preferably, the ASFV antigen-specific monocyte macrophage cell comprises CD4+T lymphocytes, CD8+Proliferation of T lymphocytes and B cells.
Preferably, the African swine fever virus antigen specific lymphocytes comprise CD4+T lymphocytes, CD8+T lymphocytes and B cells.
The invention provides a polypeptide polymer obtained by polymerizing the polypeptide in the scheme.
The invention provides application of the polypeptide or the polypeptide polymer in the scheme in preparation of a preparation for promoting a swine organism to generate African swine fever virus antigen specific immune response.
The invention provides an African swine fever virus subunit vaccine, and an active component of the subunit vaccine comprises the polypeptide or the polypeptide polymer in the scheme.
Preferably, the dosage form of the subunit vaccine comprises an injection.
Preferably, the content of the polypeptide or the polypeptide polymer in the subunit vaccine is 100 μ g/fraction.
The invention has the beneficial effects that: the invention provides a polypeptide for promoting a pig body to generate African swine fever virus antigen specific immune response; the polypeptide comprises one or more of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide and a fifth polypeptide; the amino acid sequences of the first polypeptide, the second polypeptide, the third polypeptide, the fourth polypeptide and the fifth polypeptide are respectively shown as SEQ ID NO. 1-SEQ ID NO. 5. The polypeptide can obviously promote ASFV sensitized immune cells to proliferate, and can promote a pig organism to generate ASFV antigen specific immune response by promoting pig mononuclear macrophages and B, T lymphocytes to secrete IFN-gamma. After animals are immunized, the immune response of the pig organism can be remarkably promoted. The polypeptide or the polypeptide polymer polymerized by the polypeptide can be used for preparing subunit vaccines of African swine fever viruses. The polypeptide has no toxic or side effect and biological potential safety hazard, and has industrial advantages when being used as an ASFV vaccine component.
Drawings
FIG. 1 is an identification chromatogram of AP 1;
FIG. 2 is a mass spectrum of AP 1;
FIG. 3 is an identification chromatogram of AP 2;
FIG. 4 is a mass spectrum of AP 2;
FIG. 5 is an identification chromatogram of AP 3;
FIG. 6 is a mass spectrum of AP 3;
FIG. 7 is an identification chromatogram of AP 4;
FIG. 8 is a mass spectrum of AP 4;
FIG. 9 is an identification chromatogram of AP 5;
FIG. 10 is a mass spectrum of AP 5;
FIG. 11 is a statistical chart of flow data of AP 1-AP 5 promoting proliferation of ASFV sensitized lymphocytes and mononuclear macrophages;
FIG. 12 is a statistical chart of flow data of AP 1-AP 5 promoting proliferation of lymphocytes and monocytes macrophages in healthy pigs;
FIG. 13 shows that AP1 promotes IFN-. gamma.secretion by different subtypes of immune cells;
FIG. 14 shows that AP2 promotes IFN- γ secretion by different subtypes of immune cells;
FIG. 15 shows that AP3 promotes IFN-. gamma.secretion by different subtypes of immune cells;
FIG. 16 shows that AP4 promotes IFN- γ secretion by different subtypes of immune cells;
FIG. 17 shows that AP5 promotes IFN- γ secretion by different subtypes of immune cells;
FIG. 18 is a graph of hyperimmune 14d, B lymphocyte subpopulation fraction levels;
FIG. 19 shows CD8+T lymphocyte subpopulation ratio levels.
Detailed Description
The invention provides a polypeptide for promoting a pig body to generate African swine fever virus antigen specific immune response; the polypeptide comprises one or more of a first polypeptide, a second polypeptide, a third polypeptide, a fourth polypeptide and a fifth polypeptide; the polypeptide promotes a pig body to generate an African swine fever virus antigen specific immune response by promoting the secretion of IFN-gamma by pig mononuclear macrophage and B, T lymphocyte; and/or, the polypeptide promotes the swine organism to generate African swine fever virus antigen specific immune response by promoting ASFV antigen specific monocyte macrophage proliferation.
In the present invention, the African swine fever virus antigen specific lymphocyte comprises CD4+T lymphocytes, CD8+T lymphocytes and B cells.
In the invention, the amino acid sequence of the first polypeptide is shown as SEQ ID NO.1, and specifically comprises the following steps: SMAAKIFIV (Ser-Met-Ala-Ala-Lys-Ile-Phe-Ile-Val), having an average molecular weight of 979.23g/mol and having the formula: c46H78N10O11And S. The polypeptide has a theoretical isoelectric point of pH 10.09, a GRAVY value of 1.87, and hydrophobicity. This property facilitates its binding to host proteins or cell surfaces, enabling a more efficient initiation of immune responses.
In the invention, the amino acid sequence of the second polypeptide is shown as SEQ ID NO.2, and specifically comprises: STQAYNDFL (Ser-Thr-Gln-Ala-Tyr-Asn-Asp-Phe-Leu). The average molecular weight is 1058.09g/mol, and the chemical formula is as follows: c47H67N11O17. The polypeptide has a theoretical isoelectric point of pH 3.12, a GRAVY value of-0.54, and hydrophilicity. In the prior art, no analogous compounds are known.
In the invention, the amino acid sequence of the third polypeptide is shown as SEQ ID NO.3, and specifically comprises: FQMNVSACAW (Phe-Gln-Met-Asn-Val-Ser-Ala-Cys-Ala-Trp). The average molecular weight is 1156.33g/mol, and the chemical formula is as follows: c51H73N13O14S2. The theoretical isoelectric point of the polypeptide is pH 5.25, the GRAVY value of the polypeptide is 0.63, the polypeptide has hydrophobicity, and the characteristic is favorable for the binding with host protein or cell surface, so that the immune response can be more effectively started.
In the present invention, in the case of the present invention,the amino acid sequence of the fourth polypeptide is shown as SEQ ID NO.4, and specifically comprises the following components: PPTQRVDPA (Pro-Pro-Thr-Gln-Arg-Val-Asp-Pro-Ala). The average molecular weight is 980.07g/mol, and the chemical formula is as follows: c42H69N13O14. The polypeptide has a theoretical isoelectric point of pH 7, a GRAVY value of-1.22, and hydrophilicity.
In the invention, the amino acid sequence of the fifth polypeptide is shown as SEQ ID NO.5, and specifically comprises: NSTRFTTEDP (Asn-Ser-Thr-Arg-Phe-Thr-Thr-Glu-Asp-Pro). The average molecular weight is 1167.17g/mol, and the chemical formula is as follows: c48H74N14O20. The polypeptide has a theoretical isoelectric point of pH 4.07, a GRAVY value of-1.67, and hydrophilicity.
In the invention, the polypeptide in the technical scheme is obtained by determining the sequence of an ASFV epidemic strain and predicting through computer-assisted bioinformatics, and has specificity.
The invention provides a polypeptide polymer obtained by polymerizing the polypeptide in the scheme.
The invention provides application of the polypeptide or the polypeptide polymer in the scheme in preparation of a preparation for promoting a swine organism to generate African swine fever virus antigen specific immune response.
The invention provides an African swine fever virus subunit vaccine, and an active component of the subunit vaccine comprises the polypeptide or the polypeptide polymer in the scheme.
Preferably, the dosage form of the subunit vaccine comprises an injection.
Preferably, the content of the polypeptide or polypeptide polymer in the subunit vaccine is 100 μ g/fraction.
In the present invention, the polypeptide is preferably synthesized by Shanghai Bioengineering Co., Ltd.
The invention provides a polypeptide polymer comprising a polypeptide according to the above scheme.
The invention provides application of the polypeptide or the polypeptide polymer in the scheme in preparation of a preparation for promoting a swine organism to generate African swine fever virus antigen specific immune response.
In the invention, the polypeptide or the polypeptide polymer is prepared by promoting porcine organism CD4+CD8+The T cells secrete IFN-gamma to promote the pig body to generate an African swine fever virus antigen specific immune response; or the polypeptide polymer promotes the swine organism to generate an African swine fever virus antigen specific immune response by promoting ASFV antigen specific monocyte macrophage proliferation; the ASFV antigen-specific monocyte macrophage preferably comprises CD4+T lymphocytes, CD8+Proliferation of T lymphocytes and B cells.
The invention provides an African swine fever virus subunit vaccine, and the active ingredient of the subunit vaccine comprises the polypeptide of the scheme or the polypeptide polymer of the scheme. The subunit vaccine can enhance the immunocompetence of a pig organism.
The dosage form of the preparation of the above scheme of the invention or the subunit vaccine of the above scheme comprises an injection; the content of the polypeptides or polypeptide polymers in the preparation or the subunit vaccine is 100 mug/component/head part, namely the content of each polypeptide or each polypeptide polymer is 100 mug/head part; the formulation or the subunit vaccine preferably further comprises adjuvant 50V 2; the state of the formulation or the subunit vaccine is preferably a water-in-oil emulsified state.
The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
EXAMPLE 1 solid phase Synthesis and purity measurement of the polypeptide
The polypeptide of the invention is as follows:
SEQ ID NO.1：SMAAKIFIV，AP1；
SEQ ID NO.2：STQAYNDFL，AP2；
SEQ ID NO.3：FQMNVSACAW，AP3；
SEQ ID NO.4：PPTQRVDPA，AP4；
SEQ ID NO.5：NSTRFTTEDP，AP5；
the polypeptide is synthesized by Shanghai biological engineering Co., Ltd. The detection wavelength was 214 nm. The purity of the final polypeptide purification product is more than 98%, and the structure is identified by ESI-MS, and the identification result is shown in figures 1-10, wherein figure 1 is an identification chromatogram of AP1, figure 2 is a mass spectrum of AP1, and the identification molecular weight is 979.55g/mol and is consistent with a theoretical value; FIG. 3 is an identification chromatogram of AP2, FIG. 4 is a mass spectrum of AP2, the identification molecular weight is 1058.5g/mol, which is consistent with the theoretical value; FIG. 5 is an identification chromatogram of AP3 with a peak time of 13.258 min; FIG. 6 is a mass spectrum of AP3, identifying a molecular weight of 1156.45g/mol, consistent with theoretical values; FIG. 7 is an identification chromatogram of AP4 with a peak time of 11.743 min; FIG. 8 is a mass spectrum of AP4, identifying a molecular weight of 979.9g/mol, consistent with theoretical values; FIG. 9 is an identification chromatogram of AP5 with a peak time of 12.517 min; FIG. 10 is a mass spectrum of AP5, identifying a molecular weight of 1167.95g/mol, consistent with theoretical values; as is clear from FIGS. 1 to 10, the 5 polypeptides were successfully synthesized.
Example 2 porcine lymphocyte proliferation assay
1. ASFV inactivated virus immunized pigs.
5 male long white pigs of 90 days old were immunized with an inactivated virus of an ASFV epidemic strain (from African swine fever regional laboratory, Lanzhou veterinary institute of Chinese academy of agricultural sciences) (10HID50), boosted once a month later, euthanized 7 days later, and the spleens were removed after dissection. Non-immunized healthy pigs were used as negative control group.
2. Preparation, culture and proliferation condition detection of splenocytes.
1) The collected spleens of pigs were aseptically treated with 75% alcohol, washed three times with PBS, cut into small pieces, placed in a folded sterile gauze (2 layers), and ground in a plate containing 5mL of serum 1640 medium.
2) Then, the liquid was aspirated into a 15ml centrifuge tube, and centrifuged at 1000rpm for 5 min.
3) The supernatant was discarded and the pellet (cells) was knocked to make uniform suspension.
4) Adding 10ml erythrocyte lysate, cracking for 10min, adding 6ml culture medium containing serum 1640 to stop cracking, mixing uniformly, centrifuging for 5min at 1000 rpm.
5) The supernatant was discarded, the precipitate was again knocked to be uniformly suspended, and then 10. mu.L of the suspension was diluted 40-fold and subjected to cell counting to adjust the cell concentration to 1X 106Individual cells/mL.
6) After CFSE staining, prepared splenocytes were plated in 24-well plates (1X 10)6Individual cells/well).
7) Respectively adding 0.2 mu g of the polypeptide (AP 1-AP 5) provided by the invention into CO2Culturing for 60h in an incubator, and detecting the proliferation condition of ASFV antigen-specific splenocytes by flow cytometry.
The results of the measurements are shown in FIG. 11. FIG. 11 is a flow chart showing AP 1-AP 5 as flow charts of the promotion of proliferation of ASFV-sensitized lymphocytes and monocytes and macrophages. As can be seen from FIG. 11, 5 polypeptides of the present invention significantly promoted proliferation of ASFV-specific splenic immune cells, the main type of immune cells being lymphoid mononuclear macrophages.
Healthy pig splenic lymphocytes were treated in the same manner and the effect of the polypeptide on the proliferation of non-antigen specific splenic cells in the pig organism was examined.
The results of the test are shown in FIG. 12. FIG. 12 is a statistical chart of flow data of AP 1-AP 5 promoting proliferation of lymphocytes and monocytes. As can be seen from FIG. 12, 5 polypeptides of the present invention did not significantly promote the proliferation of splenic immune cells in healthy pigs.
Example 3 detection of IFN-y secretion from different subtypes of splenic lymphocytes
The pig immunization protocol and isolation and culture of splenocytes were the same as in example 2. After obtaining the dispersed spleen cells, the single cell suspension is prepared by RPMI1640 complete culture medium, and the concentration is 1X 106And/ml. Inoculating to 24-well plate, adding 0.2 μ g of the polypeptide (AP 1-AP 5) to each well, and placing in CO2Culturing for 60h in an incubator. Cells from each well were collected, labeled with porcine CD3, CD4, CD8, and IFN-. gamma.specific antibodies, respectively, and then washed with 2% serum in PBS bufferDispersing into cell suspension for 2 times, detecting with flow cytometer, and determining B lymphocyte and CD4 respectively+T lymphocytes, CD8+T lymphocytes, CD4+CD8+Levels of IFN- γ secretion by T lymphocytes and monocytes macrophages.
The results of the detection are shown in FIGS. 13 to 17. Wherein FIG. 13 is a graph of the levels of IFN- γ secretion by different subtypes of immune cells promoted by AP 1; FIG. 14 shows that AP2 promotes IFN- γ secretion by different subtypes of immune cells; FIG. 15 shows that AP3 promotes IFN-. gamma.secretion by different subtypes of immune cells; FIG. 16 shows that AP4 promotes IFN- γ secretion by different subtypes of immune cells; FIG. 17 shows that AP5 promotes IFN- γ secretion by different subtypes of immune cells; as can be seen from FIGS. 13-17, the five polypeptides of the present invention all significantly enhance the IFN- γ secretion ability of mononuclear macrophages and B, T lymphocytes.
Example 4 polypeptide immune animal immune cell typing experiments
3 male Changbai pigs with the age of 90 days are immunized by 5 polypeptide mixtures (each polypeptide is 100 mu g/head part) of the invention, the immunization is strengthened once after one month, and the proportion of immune cells in peripheral blood is detected by a flow cytometry at 14d after the second immunization. The same volume PBS immunized group served as control.
The results of the detection are shown in FIGS. 18 to 19. Wherein FIG. 18 is the Diavoids 14d, B lymphocyte subpopulation proportion levels; FIG. 19 shows CD8+T lymphocyte subpopulation ratio levels. From fig. 18 to 19, it is known that the 5 polypeptide mixed immunity of the present invention can promote the generation of lymphocyte immune response in pig body and enhance the immunity of pig.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Sequence listing
<110> Lanzhou veterinary research institute of Chinese academy of agricultural sciences
<120> polypeptide for promoting swine organisms to generate African swine fever virus antigen specific immune response and application thereof
<160> 5
<170> SIPOSequenceListing 1.0
<210> 1
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Ser Met Ala Ala Lys Ile Phe Ile Val
1 5
<210> 2
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Ser Thr Gln Ala Tyr Asn Asp Phe Leu
1 5
<210> 3
<211> 10
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Phe Gln Met Asn Val Ser Ala Cys Ala Trp
1 5 10
<210> 4
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Pro Pro Thr Gln Arg Val Asp Pro Ala
1 5
<210> 5
<211> 10
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Asn Ser Thr Arg Phe Thr Thr Glu Asp Pro
1 5 10
Claims (5)
1. A polypeptide for promoting a pig body to generate African swine fever virus antigen specific immune response is disclosed, wherein the polypeptide is a first polypeptide or a fourth polypeptide;
the amino acid sequence of the first polypeptide is shown as SEQ ID NO. 1;
the amino acid sequence of the fourth polypeptide is shown as SEQ ID NO. 4;
the polypeptide promotes a pig organism to generate African swine fever virus antigen specific immune response by promoting the secretion of IFN-gamma by pig mononuclear macrophage and B, T lymphocyte, and/or,
the polypeptide promotes a pig body to generate African swine fever virus antigen specific immune response by promoting ASFV antigen specific mononuclear macrophage proliferation.
2. The polypeptide of claim 1, wherein the ASFV antigen-specific mononuclear macrophage cell comprises CD4+T lymphocytes, CD8+T lymphocytes and B cells.
3. Use of a polypeptide according to claim 1 or 2 in the manufacture of a formulation for promoting the production of an african swine fever virus antigen-specific immune response in a swine organism.
4. A subunit vaccine of african swine fever virus, the active ingredient of which comprises a polypeptide according to claim 1 or 2.
5. The subunit vaccine of claim 4, wherein the subunit vaccine is in a dosage form comprising an injectable formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111307559.5A CN113896771B (en) | 2020-08-26 | 2020-08-26 | Polypeptide for promoting swine organism to generate African swine fever virus antigen specific immune response and application thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010873520.9A CN112209996B (en) | 2020-08-26 | 2020-08-26 | Polypeptide for promoting swine organisms to generate African swine fever virus antigen specific immune response and application thereof |
| CN202111307559.5A CN113896771B (en) | 2020-08-26 | 2020-08-26 | Polypeptide for promoting swine organism to generate African swine fever virus antigen specific immune response and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010873520.9A Division CN112209996B (en) | 2020-08-26 | 2020-08-26 | Polypeptide for promoting swine organisms to generate African swine fever virus antigen specific immune response and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113896771A true CN113896771A (en) | 2022-01-07 |
| CN113896771B CN113896771B (en) | 2023-10-27 |
Family
ID=74059025
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111307660.0A Active CN113896772B (en) | 2020-08-26 | 2020-08-26 | Polypeptide for promoting swine organism to generate African swine fever virus antigen specific immune response and application thereof |
| CN202111307559.5A Active CN113896771B (en) | 2020-08-26 | 2020-08-26 | Polypeptide for promoting swine organism to generate African swine fever virus antigen specific immune response and application thereof |
| CN202010873520.9A Active CN112209996B (en) | 2020-08-26 | 2020-08-26 | Polypeptide for promoting swine organisms to generate African swine fever virus antigen specific immune response and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111307660.0A Active CN113896772B (en) | 2020-08-26 | 2020-08-26 | Polypeptide for promoting swine organism to generate African swine fever virus antigen specific immune response and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010873520.9A Active CN112209996B (en) | 2020-08-26 | 2020-08-26 | Polypeptide for promoting swine organisms to generate African swine fever virus antigen specific immune response and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN113896772B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080131449A1 (en) * | 2006-06-22 | 2008-06-05 | Matthias Rath | Polypeptides from African Swine Fever virus as vaccines for preventive and therapeutic use |
| CN110862435A (en) * | 2019-12-05 | 2020-03-06 | 中国农业大学 | African swine fever CTL epitope polypeptide and application thereof |
| CN110904127A (en) * | 2018-09-18 | 2020-03-24 | 瓦赫宁恩研究基金会 | African swine fever virus vaccine |
| CN111018996A (en) * | 2019-10-31 | 2020-04-17 | 河南省生物工程技术研究中心 | Neutralizing epitope subunit vaccine for African swine fever |
| CN111018995A (en) * | 2019-10-31 | 2020-04-17 | 河南省生物工程技术研究中心 | B, T cell epitope tandem fusion vaccine for African swine fever |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017187277A2 (en) * | 2016-03-07 | 2017-11-02 | Virginia Tech Intellectual Properties, Inc. | Chimeric porcine circovirus type 2 (pcv2) vaccines |
| CN110551695A (en) * | 2019-08-14 | 2019-12-10 | 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) | African swine fever virus four-gene deletion low virulent strain and application thereof |
| CN111004330A (en) * | 2019-12-13 | 2020-04-14 | 天津大学 | Method for preparing African swine fever virus P30 and P54 yeast vaccines |
-
2020
- 2020-08-26 CN CN202111307660.0A patent/CN113896772B/en active Active
- 2020-08-26 CN CN202111307559.5A patent/CN113896771B/en active Active
- 2020-08-26 CN CN202010873520.9A patent/CN112209996B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080131449A1 (en) * | 2006-06-22 | 2008-06-05 | Matthias Rath | Polypeptides from African Swine Fever virus as vaccines for preventive and therapeutic use |
| CN110904127A (en) * | 2018-09-18 | 2020-03-24 | 瓦赫宁恩研究基金会 | African swine fever virus vaccine |
| CN111018996A (en) * | 2019-10-31 | 2020-04-17 | 河南省生物工程技术研究中心 | Neutralizing epitope subunit vaccine for African swine fever |
| CN111018995A (en) * | 2019-10-31 | 2020-04-17 | 河南省生物工程技术研究中心 | B, T cell epitope tandem fusion vaccine for African swine fever |
| CN110862435A (en) * | 2019-12-05 | 2020-03-06 | 中国农业大学 | African swine fever CTL epitope polypeptide and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112209996A (en) | 2021-01-12 |
| CN113896772B (en) | 2023-08-18 |
| CN112209996B (en) | 2021-11-26 |
| CN113896772A (en) | 2022-01-07 |
| CN113896771B (en) | 2023-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20200164060A1 (en) | Herpes simplex virus vaccine epitopes specifically recognized by tissue resident memory t cells | |
| Su et al. | Adjuvant activity of chicken interleukin-12 co-administered with infectious bursal disease virus recombinant VP2 antigen in chickens | |
| CN111925417B (en) | Polypeptide for promoting pig body to generate broad-spectrum immune response and application thereof | |
| CN111944017B (en) | Polypeptide for promoting pig body to generate broad-spectrum acquired immune response and application thereof | |
| CN112209996B (en) | Polypeptide for promoting swine organisms to generate African swine fever virus antigen specific immune response and application thereof | |
| CN111944022B (en) | Polypeptide for promoting swine organisms to generate African swine fever virus antigen specific immune response and application thereof | |
| CN112209992B (en) | Polypeptide for promoting swine organisms to generate African swine fever virus antigen specific immune response and application thereof | |
| CN111925416B (en) | Polypeptide for promoting pig body to generate broad-spectrum acquired immune response and application thereof | |
| CN112159459B (en) | Polypeptide for promoting pig body to generate broad-spectrum immune response and application thereof | |
| Ohkusu‐Tsukada et al. | Adjuvant effects of formalin‐inactivated HSV through activation of dendritic cells and inactivation of myeloid‐derived suppressor cells in cancer immunotherapy | |
| CN112300248B (en) | Polypeptide for promoting pig body to generate broad-spectrum immune response and application thereof | |
| CN116808193B (en) | Recombinant protein vaccine for preventing cat infectious peritonitis and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |